Companies · Biotechnology

Volpara Health Technologies Ltd

WELLINGTON · Biotechnology

Diligence memoA one-page analyst read on Volpara Health Technologies Ltd — recommendation, valuation, rhythm, risks.
$1.5M
Total raised · real
1
Rounds
1.0×
Latest step-up
Top 77%
Sector rank · raised
Seed
Latest stage · inferred · Fri Jul 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Volpara Health Technologies Ltd looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.94× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
  • Within the normal band (94% of peer median) for its niche.
Dormant
  • Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Volpara Health Technologies Ltd is one of 4293 Biotechnology companies tracked from WELLINGTON. By capital raised it ranks in the long tail (ahead of 24% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(c)
Reg D exemption
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2016-07-01 Raised $2.0M (real) Modeled valuation $89M (est)$2.0M$89MSeed2016Seed · 2016-07-01 Raised $1.5M (real) Modeled valuation $67M (est)$1.5M$67MSeed2016Seed · 2016-07-01 Raised $1.5M (real) Modeled valuation $67M (est)$1.5M$67MSeed2016+$1.5M+$1.5MCumulative $5.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2016
Seed extension$1.5M · 2016
Seed extension$1.5M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$66.6M
Base estimate est.
$1.1M
Conservative case
$522.6M
Upside case
$7.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $88.8M · 2016-07-012016Seed · modeled $66.6M · 2016-07-01Seed · modeled $66.6M · 2016-07-012016
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
10.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
10.0 yr
On record since
2016
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.2× of median
This company$1.5M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.9× of median
This company$1.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.0× above median
This company$66.6M
Sector median$64.2M

Raised more than 24% of sector peers (real $). Modeled value above 51% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #96 of 175.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)Volpara Health Technologies Ltd (this company) Raised $1.5M · modeled $66.6M (est)Volpara Health Technologies Ltd
CompanyStageRaised · realValue · estvs peer med.
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
Captozyme Inc.Seed$3.4M$151.0M2.12×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
Volpara Health Technologies Ltd this companySeed$1.5M$66.6M0.94×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2016-07-01$10.0M$88.8M85%
Seed$1.5M2016-07-01$7.5M$66.6M90%
Seed$1.5M2016-07-01$7.5M$66.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2016-07-01
    • First recorded raise — entered as Seed.
  2. Seed$1.5M2016-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 506(c)).
  3. Seed$1.5M2016-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(c) (was Rule 506(b)).
Intelligence
Modeled next raise
$1.5M
Modeled next size est.range $1.5M$2.4M
1.0×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Roger Allen2 other2016-07
Brian Robert Leighs2016-07
David Robert Murry2016-07
John Flower Diddams2016-07
John Flower Pavlidis2016-07
John Michael Brady2016-07
Julian Robert Marshall2016-07
Lynette Mary Swinburne2016-07
Mark Robert Koeniguer2016-07
Registry & provenance

Volpara Health Technologies Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1685294
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cam Med LLCBiotechnologySeed$1.5M$66.6Msame sector · same stage
Celixir plcBiotechnologySeed$1.5M$66.6Msame sector · same stage
ILIAS WHT, Inc.BiotechnologySeed$1.5M$66.6Msame sector · same stage
miRecule, Inc.BiotechnologySeed$1.5M$66.6Msame sector · same stage
PharmaIN CorpBiotechnologySeed$1.5M$66.6Msame sector · same stage
Prospex Medical III, Inc.BiotechnologySeed$1.5M$66.6Msame sector · same stage
Wings Therapeutics, Inc.BiotechnologySeed$1.5M$66.6Msame sector · same stage
Notitia Biotechnologies CoBiotechnologySeed$1.5M$52.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Volitionrx LtdBiotechnologySeries B$110.6M89%
Renata Medical, Inc.BiotechnologySeries A$163.9M85%
Electromedical Technologies, IncBiotechnologyPre-Seed$5.8M85%
Volastra Therapeutics, Inc.BiotechnologySeries C$170.7M84%
Evida Biosciences Inc.BiotechnologySeries C$365.4M84%
Profound Medical Corp.BiotechnologySeries A$31.7M83%
Santiste Medical Inc.BiotechnologyPre-Seed$10.3M83%
Innara Health, Inc.BiotechnologySeed$66.3M83%
Frequently asked
How much funding has Volpara Health Technologies Ltd raised?
Volpara Health Technologies Ltd has raised approximately $1.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Volpara Health Technologies Ltd's estimated valuation?
Provath's modeled valuation for Volpara Health Technologies Ltd is approximately $66.6M (modeled range $1.1M–$522.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Volpara Health Technologies Ltd at?
Volpara Health Technologies Ltd's latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Jul 01.
What does Volpara Health Technologies Ltd do and where is it based?
Volpara Health Technologies Ltd operates in the Biotechnology sector, based in WELLINGTON.
Explore related

See where Volpara Health Technologies Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Volpara Health Technologies Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.